Abstract: The present invention relates to compositions which disinfect skin, whilst also being safe to use on skin. The compositions of the invention are also able to disinfect surfaces.
Abstract: Topical disinfectant compositions for sanitizing skin or other surfaces or increasing the surfaces' resistance to microbe transmission according to certain embodiments include ethyl alcohol, chlorhexidine, an ester-containing moisturizer and water, and optionally also include one or more of a surfactant, a preservative, colloidal silver and hydrogen peroxide. Alternative topical disinfection compositions for sanitizing skin or other surfaces or increasing the surfaces' resistance to microbe transmission include hydrogen peroxide, chlorhexidine, an ester-containing moisturizer and water, and optionally also include one or more of a surfactant, a preservative and colloidal silver.
Abstract: According to the invention, at least one tyrosine derivative, in particular N-Palmitoyl-O-methyl-L-Tyrosine, is used for a cosmetic or nutraceutical treatment and/or the manufacture of a cosmetic or nutraceutical composition for improving the general condition of the skin and/or its appendages, in particular for a pro-pigmentation effect.
Abstract: A physically stable, uniform, skin care serum composition that contains a polymer system, a skin care active, and a liquid carrier. The polymer system includes microcrystalline cellulose, Sphingomonas ferment extract, and cellulose gum.
Type:
Application
Filed:
May 17, 2024
Publication date:
November 21, 2024
Inventors:
Lindsey Michelle Britt, Shawn David McConaughy
Abstract: The present disclosure provides polyester elastomers, polyester elastomer compositions, and methods of preparing polyester elastomers and polyester elastomer compositions. The polyester elastomers in the present disclosure are prepared by reacting at least one di-carboxylic acid or tri-carboxylic acid, at least one mono-carboxylic acid, and at least one polyol. The crosslinked polyester elastomers can be formulated into various personal care formulations.
Type:
Application
Filed:
March 27, 2024
Publication date:
November 21, 2024
Inventors:
Xu QIN, Greg WANG, Mark David WESTMEYER, Polina TSUPKO, Amar PAWAR, Sigfredo GONZALEZ, Benjamin FALK, Alok SARKAR
Abstract: A method for treating keratinous material, including human hair is provided. The method includes such steps as (1) providing an agent (a), the agent (a) containing: (a1) at least one amino-functionalized silicone polymer, and (2) providing an agent (b), the agent (b) comprising: (b1) at least one alkylene glycol of formula (AG), where x is an integer from 1 to 10000, and (b2) at least one solvent selected 1,2-propylene glycol, propylene carbonate, 1,3-propylene glycol, 1,2-butylene glycol, dipropylene glycol, ethanol, isopropanol, diethylene glycol monoethyl ether, glycerol, phenoxyethanol and benzyl alcohol, and optionally providing an agent (c) that includes at least one pigment. The agents (a) and (b) and optionally (c) can be mixed and applied to keratinous material, such as human keratinous material, allowed to act on the hair, and optionally rinsed form the keratinous material.
Abstract: A method for coloring keratin fibers, in particular human hair, including applying a coloring agent (F) to the keratin fibers and applying a shampoo (S) to the keratin fibers. The coloring agent includes at least one amino-functionalized silicone polymer, and at least one pigment, and the shampoo includes at least one amino-functionalized silicone polymer. The coloring agent (F) and the shampoo (S) are different formulations.
Type:
Application
Filed:
July 26, 2024
Publication date:
November 21, 2024
Inventors:
Constanze Kruck, Claudia Kolonko, Marcus Claas, Gabriele Weser
Abstract: A cosmetic composition for application to the skin comprising a first ingredient (1) which comprises the aerial plant parts of the royal fern, water and polyhydric alcohols, and further comprising a second ingredient (2) which comprises a liposomally encapsulated form of the first ingredient (1).
Abstract: The present invention relates to a health functional food, a food and a cosmetic composition for anti-oxidation, wrinkle improvement, elasticity improvement and skin moisturizing comprising a complex of an Indian gooseberry (Phyllanthus emblica) extract and a barley sprout (Hordeum vulgare) as an active ingredient. The complex provided from the present invention has excellent DPPH scavenging activity, elastase inhibitory activity, MMP-1 inhibitory activity and hyaluronic acid content increasing effect, so it can be used as a health functional food, a food and a cosmetic composition for anti-oxidation, wrinkle improvement, elasticity improvement and skin moisturizing.
Type:
Application
Filed:
September 29, 2022
Publication date:
November 21, 2024
Inventors:
Hae-Yeon LEE, Jong-Lae KIM, Sung Bin IM, So Young KIM
Abstract: The disclosed subject matter provides systems and methods for delivering a therapeutic agent for targeted treatments. The system can include at least one microcapsule and a magnetic system. The microcapsule can include the therapeutic agent and a layer of iron oxide nanoparticles (IONPs). The therapeutic agent can be encapsulated by the layer of the IONPs that include a first type of nanoparticles and a second type of nanoparticles. The magnetic system can be configured to generate a magnetic field to control the motion of the microcapsule as well as to assemble into multi-capsule structure and control its motion. Assemblies of multiple microcapsules can be controlled simultaneously and directed to targeted areas for delivery of larger therapeutic payload.
Type:
Application
Filed:
May 20, 2024
Publication date:
November 21, 2024
Applicant:
THE TRUSTEES OF THE UNIVERISTY OF PENNSYLBANIA
Inventors:
Hyun Koo, Edward Steager, Daeyeon Lee, Hong-Huy Tran
Abstract: The present application relates to a composition comprising an antigen-binding fragment and an excipient. The antigen-binding fragment comprises an immunoglobulin single variable domain capable of specifically binding to PD-L1 and comprising CDR1-3, the CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 47, and the excipient may comprise proline. The composition has good stability and suitable viscosity and can be used for subcutaneous injection.
Type:
Application
Filed:
September 16, 2022
Publication date:
November 21, 2024
Inventors:
Ting Xu, Kangping Guo, Lihong Yun, Yuanli Wu, Yan Huang, Hongqin Hu
Abstract: A bioorthogonal catalytic patch integrates TiO2 nanosheets populated with metallic nanoparticles into polyvinyl alcohol-based microneedles arranged in an array. This bioorthogonal patch-based device is robust, removable and can effectively mediate the conversion of caged substrates into their active states once placed at the site of application. The capacity of the patch in executing bioorthogonal catalysis in high-level living systems was demonstrated by localized dealkylation of a caged doxorubicin prodrug at the melanoma tumor site and restoration of its pharmacological properties for cancer therapy. This in situ applied patch facilitated to enhance the local treatment efficacy and eliminate off-targeted prodrug activation or dose-dependent side effect towards healthy organs or tissues located away from the application site.
Type:
Application
Filed:
April 27, 2021
Publication date:
November 21, 2024
Applicants:
THE REGENTS THE UNIVERSITY OF CALIFORNIA, NORTH CAROLINA STATE UNIVERSITY
Abstract: Aspects of the present disclosure include polymeric structures (e.g., microneedles) having a lattice microstructure composed of one or more lattice cell units. Polymeric structures according to certain embodiments have repeating lattice cell units that are formed by high resolution continuous liquid interface production. Aspects also include systems for making polymeric structures having a lattice microstructure. Systems according to certain embodiments include a micro-digital light projection system having a light beam generator component and a light projection monitoring component and a liquid interface polymerization module having a build elevator and a build surface configured for generating the polymeric lattice microstructure from a polymerizable composition positioned therebetween. Methods for making polymeric structures having a lattice microstructure with the subject systems are also provided.
Type:
Application
Filed:
September 22, 2022
Publication date:
November 21, 2024
Inventors:
Joseph M. DeSimone, Gunilla B. Jecobson, Maria T. Dulay, Brian J. Lee, Kai-Wen Hsiao, Netra Rajesh, Madison M. Driskill, Audrey Shih, Jillian Perry, Shaomin Tian
Abstract: The present disclosure relates to parenteral nutritional formulations, including ready-to-use parenteral nutrition formulations. More particularly, the present disclosure is directed to lipid formulations or emulsions and multi-chamber containers comprising same, wherein the lipid emulsion contains glycerophosphorylcholine as a choline source. The present disclosure further relates to methods of providing choline to a patient in need of parenteral nutrition and methods of avoiding and/or treating choline deficiency and liver damage.
Abstract: Salt-based non-therapeutic hygienic formulations or compositions or therapeutic formulations or compositions, for example those rich in calcium, are effective against airborne pathogens, suppressing virus shedding, for instance by increasing a surface viscoelasticity of airway lining fluid. Associated apparatus, methods and articles are used to deliver salt-based non-therapeutic hygienic formulations or compositions as hygienic treatments to the upper respiratory tract. Associated apparatus, methods and articles are used to deliver salt-based therapeutic antimicrobial formulations or compositions to the upper respiratory tract. For example, nasal delivery of calcium-rich salines with aerosol droplet size of around 10 ?m (e.g., 7 ?m-15 ?m, or more preferably 9 ?m-10 ?m) may advantageously limit distribution to the nose and upper airways of the respiratory tract, suppressing bioaerosol generation.
Type:
Application
Filed:
July 10, 2024
Publication date:
November 21, 2024
Inventors:
David A. Edwards, Thomas E. Devlin, Dennis Arthur Ausiello
Abstract: A pharmaceutical composition for treating retinal degeneration is provided. Particularly, the pharmaceutical composition includes a tropomyosin 1 (TPM1) inhibitor and is further enriched with pharmaceutically acceptable additives. In addition, the pharmaceutical formulation is configured to suppress and/or knock down the expression and/or activity of TPM1, thereby addressing the molecular factors associated with retinal degeneration.
Abstract: The present invention refers to a composition comprising eriodictyol and guaifenesin. In particular, the present invention refers to a composition comprising criodictyol and guaifenesin, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of eriodictyol and guaifenesin for the preparation of a pharmaceutical composition. Finally. the present invention relates to the use of eriodictyol for masking or inhibiting the bitter taste of guaifenesin or guaifenesin comprising compositions.
Type:
Application
Filed:
July 26, 2024
Publication date:
November 21, 2024
Inventors:
Joachim Hans, Jakob Ley, Martin Gurney, Veronika Somoza, Leopoldo Beltran
Abstract: The invention provides gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, with release rate-modulating films and methods for making and using such systems. The release rate-modulating films provide good control over release of agents (such as therapeutic, diagnostic, or nutritional agents) present in the gastric residence system. The films also permit higher drug loading in the gastric residence systems and components of gastric residence systems while maintaining good control over release of agents. Some embodiments of the films can provide resistance against burst release of agent upon exposure to alcohol.
Type:
Application
Filed:
May 17, 2024
Publication date:
November 21, 2024
Inventors:
Rosemary KANASTY, Nupura BHISE, Stephen ZALE, Bennett CARTER, Jung Hoon YANG, Andrew BELLINGER, Susan LOW, James WRIGHT, David ALTREUTER, Colin GARDNER
Abstract: A metered dose inhaler comprising a metering valve, a canister, an actuator comprising an actuator nozzle, wherein the canister comprises a formulation, the formulation comprising greater than 70% by weight of propellant HFO-1234ze(E), and at least one active pharmaceutical ingredient dissolved in the formulation to form a solution, said active pharmaceutical ingredient preferably selected from beclomethasone, formoterol or tiotropium.
Type:
Application
Filed:
September 8, 2022
Publication date:
November 21, 2024
Inventors:
Philip COCKS, Alexander SLOWEY, Benjamin MYATT, Sarah WRIGGLESWORTH, James LISTER, Lauren HARRISON, Chad HARALDSON, Joseph MILLER, James DRAKE, Stephen STEIN
Abstract: Provided herein are compositions and methods for treating cancer of a body cavity, including urinary tract cancer, by way of a combination of at least one immunomodulatory agent, such as a CTLA-4 antibody or TLR agonist, and optionally one chemotherapeutic agent, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
Abstract: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.
Abstract: Described are polymeric micelle nanoparticles and their use in producing extracellular vesicles containing a cargo molecule. The cargo-loaded extracellular vesicles can be used as therapeutic delivery vectors.
Abstract: An external nano liniment for gout and a preparation method thereof are provided. The external nano liniment for gout includes a cream phase and nanoparticles dispersed in the cream phase, wherein the nanoparticles are a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, an active ingredient used for treating gout is embedded or dispersed in the water phase and/or the oil phase of the nanoparticles, and a size distribution of the nanoparticles is in a range of 1-200 nm.
Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
Type:
Application
Filed:
December 12, 2023
Publication date:
November 21, 2024
Inventors:
Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
Abstract: The present invention relates to a cationic liposome that binds and stabilises RNA, its use and a method for loading the liposome with emetine. The liposome consists of neutral lipids in the amount of 12.4 to 49% by weight, cationic lipids in the amount of 16.2 to 55% by weight, polyethylene glycol-modified lipids in the amount of 12.9 to 15.1% by weight and cholesterol in an amount from 15.4 to 18.1% by weight, and is characterised by a size from 80 nm to 190 nm, a polydispersity index from 0.06 to 0.23, and a zeta potential from +19 mV to +55 mV, wherein it is loaded with RNA.
Abstract: Formulations are provided for the oral administration of avanafil, a Type V phosphodiesterase inhibitor (“PDE V inhibitor”), and analogs thereof. The formulations are orally disintegrating tablets (ODTs) that rapidly dissolve or disintegrate in the oral cavity. The tablets contain an absorption enhancing composition that increases the duodenal absorption of the active agent, following transfer from the low pH environment of the stomach to the more basic pH of the duodenum. Methods for administering the active agent using the dosage forms are provided. The invention also encompasses a method of selecting components and compositions to incorporate in the formulations which will facilitate increased absorption of the active agent in the duodenum and thus serve as “absorption enhancing compositions” herein. Also provided are methods for manufacturing orally disintegrating tablets to optimize the physical properties of the dosage forms, particularly hardness and disintegration time.
Abstract: A novel orally administrable dosage form including a drug/active layer for loading a therapeutic agent and an extension layer for retaining the API or drug dosage form in the stomach of a subject in need thereof. Also disclosed is a method of treating diseases with the dosage form.
Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form comprising mesoporous silica using a 3D printing process. The process is a printing process that allows the production of solid pharmaceutical administration forms comprising drug loaded mesoporous silica in an easy and flexible manner and in conformity with the high-quality standards required for the production of pharmaceutical.
Type:
Application
Filed:
July 5, 2022
Publication date:
November 21, 2024
Applicant:
Merck Patent GmbH
Inventors:
Malte BOGDAHN, Stefan SCHILLER, Meike HARMS, Daniel Joseph PRICE, Marcel WEDEL, Simon GEISSLER, Finn BAUER
Abstract: Compositions comprising degradable polymers combined with nucleic acids, such as DNA and RNA, encoding antigen and their use as genetic vaccines are disclosed.
Type:
Application
Filed:
September 28, 2022
Publication date:
November 21, 2024
Inventors:
Jordan J. GREEN, Elana BEN-AKIVA, Johan KARLSSON, Stephany Yi TZENG, Kelly RHODES, Sarah Y. NESHAT
Abstract: The invention provides a pharmaceutical composition comprising: a) a high molecular weight poloxamer; b) a low molecular weight poloxamer; c) a DNAzym; d) a pharmaceutically acceptable buffer; wherein the composition is liquid at room temperature or below and solid or semisolid at a temperature of 36° C. or higher. The composition is particular suitable for the treatment of intestinal diseases, in particular inflammatory intestinal diseases.
Type:
Application
Filed:
September 28, 2022
Publication date:
November 21, 2024
Inventors:
Thomas Rupp, Daniel Bock, Rolf Krattenmacher, Georgios Sarigiannis, Caria Prata
Abstract: The present invention generally relates to enteric-coated particles containing lactoferrin. More specifically, the present invention provides an enteric-coated particle comprising (or consisting essentially of): a) a core comprising (or consisting essentially of) an inert core-forming material selected from cellulose polymer, sugar, sugar alcohol, starch and carnauba wax; b) a first coating layer substantially covering the core and comprising (or consisting essentially of) b-1) lactoferrin, b-2) a pharmaceutically acceptable binder and optionally b-3) one or more other suitable excipients, such as a plasticizer; and c) a second coating layer substantially covering the first coating layer and comprising (or consisting essentially of) c-1) an enteric coating material, and optionally c-2) one or more suitable excipients, such as a plasticizer and/or an anti-tacking agent.
Type:
Application
Filed:
September 12, 2022
Publication date:
November 21, 2024
Inventors:
Blaš Grilc, Maja Bjelosevic, Robert Roskar, Nika Osel, Albin Kristl, Mirjana Gasperlin
Abstract: Provided herein are pharmaceutical compositions comprising a lipid nanoparticle (LNP) and a therapeutic nucleic acid (TNA), wherein the LNP comprises a single-chain variable fragment (scFv) linked to the LNP, and at least one pharmaceutically acceptable excipient. The scFv is capable of binding an antigen present on the surface of a cell, advantageously providing LNP compositions that target only those cells or tissues expressing the receptor.
Abstract: Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.
Type:
Application
Filed:
May 17, 2024
Publication date:
November 21, 2024
Applicant:
SMITH & NEPHEW, INC.
Inventors:
Lei SHI, Aleksa JOVANOVIC, Dennis CARSON
Abstract: The present invention relates to the treatment and/or monitoring of subjects suffering from, or susceptible to, Wilson's Disease, and involves measuring the serum non-ceruloplasmin (NCC) level in a subject and determining whether the serum NCC level is within a specified range. Treatment regimes can be adjusted if appropriate to control the subject's serum NCC level to be within the desired range.
Type:
Application
Filed:
April 26, 2022
Publication date:
November 21, 2024
Inventors:
Naseem Amin, Timothy James Morley, Omar Kamlin
Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.
Type:
Application
Filed:
December 19, 2023
Publication date:
November 21, 2024
Applicant:
National University Corporation Chiba University
Abstract: The present invention is directed to the use of the compound Prc-210. or a pharmaceutically acceptable acid addition salt thereof. for use in the treatment of an inflammation in a tissue of a subject, which inflammation is caused by an acute tissue injury.
Type:
Application
Filed:
July 14, 2022
Publication date:
November 21, 2024
Inventors:
William FAHL, Torsten GOESCH, Hannah Rebecca GOESCH, Sarah Ricarda GOESCH
Abstract: This present disclosure is directed to use of small organic molecules calcium and sodium channel blockers as potential pharmacotherapeutics for diseases involving modulation of one or more calcium and/sodium channels (such as epilepsy).
Type:
Application
Filed:
April 18, 2024
Publication date:
November 21, 2024
Inventors:
Patrice L. Jackson-Ayotunde, Rhashanda D. Haywood, Miguel Martin, Isis Jemiyotan Amaye
Abstract: Systems and methods for treating a fibrous mass, which is comprised of a Morton's neuroma, are disclosed. In one exemplary implementation, a method may comprise identifying a location of the fibrous mass and non-surgically delivering electromagnetic energy to the fibrous mass. Embodiments may include delivering the energy via a Nd:Yag laser at various specified parameters, such as duration, pulse count, and tissue depth, among others.
Abstract: The present invention relates to a composition comprising:-at least one molecule covalently conjugated to a polylysine, and-at least one hydrophobic molecule which cannot be covalently conjugated to a polylysine, said molecule being encapsulated in a micelle, and/or at least one molecule conjugated to a polylysine by polymerization, said molecule and the polylysine forming a copolymer. The subject matter of the invention is also the method for producing said composition and/or the uses thereof.
Abstract: The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin, water, and an amine, and has a pH above the buffering range of the amine. The liquid formulation of the invention is stable and ready-to-use.
Abstract: Disclosed herein are compositions comprising two or more sleep-inducing agonists and/or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.
Abstract: The present disclosure is directed to compositions and methods for the generation of S-nitrosoacetylcysteine (SNOAC) for stable administration in the improvement, treatment and/or prevention of conditions that benefit from increased bioavailable nitric oxide. The present methods allow generation and delivery of SNOAC through various administration routes, including sublingually, orally, and through inhalation of aerosolized formulations. SNOAC is generated through a reaction between N-acetylcysteine and a nitrite compound in an aqueous medium.
Abstract: The present invention relates to a composition comprising at least the following molecules: oleic acid, palmitic acid, lauric acid, linoleic acid, azelaic acid, farnesylcysteine, palmitoleic acid, cholesterol, thioctic acid, myristic acid, orotic acid, acetic acid, butyric acid, lactic acid, propionic acid, and/or a salt and/or an ester and/or an anhydride of one or more of these molecules, and use thereof in particular as medicine.
Abstract: The present disclosure relates to methods of treating diseases. More particularly, the disclosure relates to methods of adjuvant therapy. Disclosed herein are methods of promoting 8-hydroxyoctanoic acid (8-HOA) production and thereby treating diseases. The method includes administering for a first period of time a first dosage form including eicosapentaenoic acid (EPA) to a patient. After expiration of the first period of time, the patient is then administered for a second period of time a second dosage form including gamma-linolenic acid (GLA).
Abstract: The invention provides a method for improving the feed intake of domesticated animals such as husbandry animals and pets, and humans, more particularly for pigs and piglets. The method is directed to offering of a composition that comprises benzocaine and feed ingredients that have been adjusted to the needs of the animal concerned. It also provides a composition suitable for use in the method according to the invention.
Type:
Application
Filed:
September 1, 2022
Publication date:
November 21, 2024
Applicant:
OREXA B.V.
Inventors:
Bernardus Wijnand Mathijs Marie PEETERS, Antje Johanna ZONNEVELD
Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 15 and 1,000 Centipoise per unit area.
Type:
Application
Filed:
July 26, 2024
Publication date:
November 21, 2024
Inventors:
Olof Mikael TROLLSAS, John J. STANKUS, Shahram Shawn GHOLAMI
Abstract: Methods for treating a coronavirus infection in a subject, which include administering to the subject a therapeutically effective amount of an agent selected from one or more of artesunate, dihydroartemisinin, isorhamnetin, lycorine, (+)-taxifolin, baicalin, tashinone I, and desethylamodiaquine. Pharmaceutical compositions including in a pharmaceutically acceptable carrier, two or more agents selected from the group consisting of artesunate, dihydroartemisinin, isorhamnetin, lycorine, (+)-taxifolin, baicalin, tashinone I, desethylamodiaquine, artemisinin, nirmatrelvir and ritonavir, nirmatrelvir, ritonavir, baicalein, rhamnetin, (?)-taxifolin, and cryptotanshinone.
Abstract: Disclosed are non-aqueous solid and liquid compositions comprising resiniferatoxin and a surfactant. The non-aqueous solid and liquid compositions may be used to prepare aqueous compositions that are used in the treatment of pain, specifically osteoarthritis-related joint pain. Moreover, also disclosed are kits containing the non-aqueous solid and liquid compositions and a diluent and methods of preparing the compositions. The non-aqueous solid and liquid compositions allow for longer storage and recovery of resiniferatoxin compared to resiniferatoxin alone prior to reconstitution with a diluent.
Type:
Application
Filed:
July 29, 2024
Publication date:
November 21, 2024
Applicant:
GRUENENTHAL GMBH
Inventors:
Andreas BERNKOP-SCHNUERCH, Olivier VALDENAIRE, Thomas GILLER
Abstract: The present invention, in some embodiments, is directed to a pharmaceutical composition including ?-caryophyllene and a statin, and use of same, such as in a method for treating a subject afflicted with a bone-related disease or a disorder associated therewith.